News Powered By:
– a collaborative partner.
CenterWatch : August 18, 2017 1:59 pm : Centerwatch, IBM, JDRF, R&D Trends, United States
IBM and JDRF, a global organization funding type 1 diabetes (T1D) research, announced a new collaboration to develop and apply machine learning methods to analyze years of global T1D research data and identify factors leading to the onset of T1D in children. T1D affects approximately 1.25 million Americans, and it currently does not have a […]
The post JDRF, IBM to research risk factors for pediatric type 1 diabetes in children appeared first on CenterWatch News Online.
CenterWatch : August 18, 2017 1:56 pm : Addario Lung Cancer Medical Institute, Centerwatch, Champions Oncology, Global News, R&D Trends
Champions Oncology, a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, announced a collaboration with The Addario Lung Cancer Medical Institute (ALCMI) to develop a novel cohort of PDX models in patients with ROS1 gene rearrangement. These models will further expand […]
The post Champions Oncology, Addario Lung Cancer Medical Institute partner appeared first on CenterWatch News Online.
CenterWatch : August 18, 2017 1:53 pm : Centerwatch, Drug Sponsors, United States
LifeNet Health, a global regenerative medicine company, has announced that it will invest $12.25 million to expand its global headquarters operation in the City of Virginia Beach. The non-profit will add a 100,000-square-foot warehouse, 20,000 square feet of office space, and an 18,000-square-foot R&D and production facility across three campuses. Virginia successfully competed against Florida, […]
CenterWatch : August 18, 2017 11:38 am : Centerwatch, Curtana Pharmaceuticals, Ethics/Regulatory, Halloran Consulting Group, United States
Halloran Consulting Group, a national consultancy serving biotech, pharma, & medical device companies with clinical, quality and regulatory compliance projects, announced their role as U.S. regulatory consultants for Curtana Pharmaceuticals. The FDA granted orphan drug designation to CT-179, Curtana Pharmaceuticals’ lead Olig2 inhibitor for the treatment of gliomas, including glioblastoma (GBM) in adults and pediatric high-grade […]
The post Halloran announces role as regulatory lead for Curtana’s CT-179 Orphan designation appeared first on CenterWatch News Online.
CenterWatch : August 17, 2017 10:07 am : Cedars-Sinai Medical Center, Centerwatch, Context Therapeutics, Fred Hutchinson Cancer Research Center, Global News, R&D Trends, Synergie Lyon Cancer
Context Therapeutics, a biotechnology company dedicated to creating new medicines for cancer, fibrosis and neurodegenerative disease, has entered into agreements with three research partners. The company will collaborate with experts in the field of Sigma1 protein and its role in disease biology at the Cedars-Sinai Medical Center, Fred Hutchinson Cancer Research Center and Synergie Lyon […]
The post Context Therapeutics initiates three research collaborations appeared first on CenterWatch News Online.